Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers

AIDS

Volumn 12, Issue 18, 1998, Pages 2407-2415

  Belshe, Robert B ^a,j   Gorse, Geoffrey J ^a   Mulligan, Mark J ^b   Evans, Thomas G ^c   Keefer, Michael C ^b   Excler, Jean Louis ^d   Duliege, Anne Marie ^e   Tartaglia, James ^f   Cox, William I ^f   McNamara, James ^g   Hwang, Kai Lin ^h   Bradney, Alice ⁱ   Montefiori, David ⁱ   Weinhold, Kent J ⁱ  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^d Pasteur Merieux Connaught (PMC)   (France)

^e NOVARTIS PHARMA AG   (Switzerland)

^f Virogenetics Corporation   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h EMMES CORPORATION   (United States)

ⁱ DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j S LOUIS UNIV HLTH SCIENCES CENTER   (United States)

more..

Author keywords

Cytotoxic T cells; HIV vaccines; Neutralizing antibody

Indexed keywords

CD8 ANTIGEN; GAG PROTEIN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; VIRUS ENVELOPE PROTEIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOUBLE BLIND PROCEDURE; ERYTHEMA; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; INJECTION PAIN; MULTICENTER STUDY; NONHUMAN; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; POXVIRUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 7844229165     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199818000-00009     Document Type: Article

References (21)

1. Fries LF, Tartaglia J, Taylor J, Kauffman EK, Meignier B, Paoletti E: Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative pox virus vector system. Vaccine 1996, 14:428-434.
2. Taylor I, Weinberg R, Tartaglia J, et al.: Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins. Virology 1992, 187:321-328.
3. Taylor I, Meignier B, Tartaglia J, et al.: Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG(vCP65) in non-avian species. Vaccine 1995, 13:539-549.
4. Musey L, Hughes J, Schacker T, Shea T, Corey L, McElrath MJ: Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997, 337:1267-1274.
5. Graham BS, Belshe RB, Clements ML, et al.: Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. J Infect Dis 1992, 166:244-252.
6. Corey L, McElrath MJ, Weinhold K, et al.: Cytotoxic T cell and neutralizing antibody responses to HIV-1 envelope with a combination vaccine regimen. J Infect Dis (in press).
7. SF2 recombinant gp120, or both vaccines in seronegative adults. J Infect Dis, 1998, 177:1230-1266.
8. Cooney EL, McElrath MJ, Corey L, et al.: Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc Natl Acad Sci USA 1993, 90:1882-1886.
9. Graham BS, Matthews TJ, Belshe RB, et al.: Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. J Infect Dis 1993, 167:533-537.
10. Graham BS, Gorse GJ, Schwartz DH, et al.: Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. J Infect Dis 1994, 170:782-786.
11. Excler JL, Plotkin S: The prime-boost concept applied to HIV preventive vaccines. AIDS 1997, (Suppl A) 11:S127-S137.
12. Fleury B, Janvier G, Pialoux G, et al.: Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp160 or HIV-1 and boosted with a recombinant gp160. J Infect Dis 1996, 174:734-738.
13. Pialoux G, Excler J-L, Riviere Y, et al.: A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). AIDS Res Hum Retrovirol 1995, 11:373-381.
14. Cadoz M, Strady A, Meignier B, et al.: Immunization with canarypox virus expressing rabies glycoprotein. Lancet 1992, 339:1429-1432.
15. Kahn JO, Sinangil F, Baenziger J, et al.: Clinical and immunological responses to human immuno-deficiency virus (HIV) type 1 SF-2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. J Infect Dis 1994, 170:1288-1291.
16. Belshe RB, Clements ML, Dolin R, el al.: Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. J Infect Dis 1993, 168:1387-1395.
17. Pilgrim AK, Pantaleo G, Cohen OJ, et al.: Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis 1917, 176:924-932.
18. Montefiori DC, Pantaleo G, Fink LM, et al.: Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term non-progressors. J Infect Dis 1996, 173:60-67.
19. Zolla-Pazner S, Alving C, Belshe R, et al.: Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines. J Infect Dis 1997, 175:764-774.
20. Montefiori DC, Collman RG, Fouts TR, et al.: Evidence that antibody-mediated neutralization of human immunodefiency virus type 1 by sera from infected individuals is independent of coreceptor usage. J Virol 1998, 72:1886-1893.
21. Corey L, Weinhold K, Montefiori D, et al.: Combination candidate HIV vaccines using a canarypox vector (vCP205) followed by boosting with gp120 SF-2. 4th Conference on Retroviruses and Opportunistic Infection. Washington DC, 1997 [Abstract LB18].